[ad_1]
This was announced on Tuesday by the portal vz.lt.
V. Bumelis acquired a 5-hectare parcel for this investment in the Vilnius district, near the Molėtai road, where the companies Arginta and Brolis Semiconductors already operate.
“Because I don’t really like investing in land, I like investing in equipment (…) I’m looking for investors because I don’t have that amount of money,” he told BNS.
He said it was planned to develop the Celltechna project on the site, to build three new factories. One would produce products from microbial cells, another from mammalian cells, and a third from stem cells, including 3D bioprinting.
“It is the proliferation of all types of cells, their multiplication and, in the future, the impression of various organs. It involves three factories, in addition to a huge scientific research center and another small gene therapy complex”, said the researcher .
“Nothing will be done in biotechnology without research centers, if only production is developed, it will fail,” he added.
According to him, first of all, it is planned to implement a project of a gene therapy complex.
“Gene therapy is now available upper part biotechnology and biopharmaceuticals are evolving at a fabulous rate. I can say that the entire United States is in a gene therapy boom and we can develop it perfectly here, “said V. Boumelis.
Offers to invest in the state too
The scientist says he has offered the state to participate in the construction of a new production and research complex, but has not yet received a concrete response.
“I said to the state itself – maybe you want to invest? If you want to invest in state banks or pharmacies, you can also invest in factories and (state – BNS) would be a shareholder, what happens here? It is possible to be a privateer alongside the state, because We are all citizens of the same state ”, considered V. Bumelis.
“I appealed to the government, I say, so many millions are needed. They say, “Oh professor, it’s interesting, it’s interesting and it doesn’t exist anymore,” he said.
However, V. Bumelis did not rule out the possibility that the government contributes to the project.
“The state has said that in 10 years it will produce 5 percent of biotechnologies. GDP. That is around $ 2.5 billion. Euros. Where are you going to earn those billions, from those small investments that are being made here? Right now, when you divide the money into one, the second or the third? They (money – BNS) can only be collected from a large biotech industry, “he emphasized.
He said he hoped that the big biotech companies could come to Lithuania and invest large sums.
“There should be a corporate investor here who can then produce those products. It is usually a pharmaceutical company that wants to add the products I mentioned to its portfolio, they can be generic and innovative pharmaceutical companies ”, said V. Bumelis.
“Lithuania is a really good country to develop research; we have a lot of smart people trained in biological sciences. There are really no big problems here, universities are training people, they are not worse. All Lithuanians are smart, investment conditions they are good, ”he said.
Priority area call
The government affirms that biotechnology is a priority area for economic development, which should represent at least 5% by 2030. GDP of the country.
The foreign investment development agency “Invest in Lithuania” points out that now the life sciences sector – there are 72 biotechnology companies operating in the country – does not generate even 1 percent. GDP.
Mantas Katinas, director of “Invest in Lithuania”, told BNS that the agency offers the state to clearly name the priority sectors of the economy, which should include life sciences. In recent years, the agency has commissioned several studies to assess the country’s environment for life science investors.
Several big, world-famous names already operate in Lithuania: Teva Baltics (formerly Sicor Biotech), the Lithuanian biopharmaceutical leader of the international generic drug maker Teva. “Invest in Lithuania” indicates that the latter, led by V. Bumelis for 13 years, has invested more than 80 million in Lithuania. AMERICAN DOLLAR.
In addition, Thermo Fisher Scientific Baltics, a manufacturer of medical and scientific equipment, operates here. It acquired US dollars from Fermentas, Intersurgical, Hollister, and others.
[ad_2]
